Hypoxia Targeted Gene Therapy to Increase the Efficacy of Tirapazamine as an Adjuvant to Radiotherapy: Reversing Tumor Radioresistance and Effecting Cure

Cancer Research

Volumn 64, Issue 4, 2004, Pages 1396-1402

  Cowen, Rachel L ^a   Williams, Kaye J ^a   Chinje, Edwin C ^a   Jaffar, Mohammed ^a   Sheppard, Freda C D ^a   Telfer, Brian A ^a   Wind, Natasha S ^a   Stratford, Ian J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; TIRAPAZAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG EFFICACY; GENE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIA RESPONSIVE ELEMENT; LACTATE DEHYDROGENASE GENE; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RADIOSENSITIVITY; RAT; SOLID TUMOR; TUMOR MODEL; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CELL HYPOXIA; FEMALE; GENE THERAPY; HUMANS; L-LACTATE DEHYDROGENASE; MICE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NEOPLASMS, EXPERIMENTAL; RADIATION TOLERANCE; RADIOTHERAPY, ADJUVANT; RESPONSE ELEMENTS; TRIAZINES;

EID: 1242271216     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2698     Document Type: Article

References (46)

1. 2 tension measurements. Cancer Res., 51: 3316-3322, 1991.
2. 2 tension measurements. Cancer Res., 51: 6098-6102, 1991.
3. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., and Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys., 1: 285-289, 1997.
4. Brizel, D. M., Dodge, R. K., Clough, R. W., and Dewhirst, M. W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol., 53: 113-117, 1999.
5. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56: 4509-4515, 1996.
6. Stratford, I. J., and Workman, P. Bioreductive drugs into the next millennium. Anticancer Drug Des., 13: 519-528, 1998.
7. Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., and Lee, W. W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12: 1239-1242, 1986.
8. Brown, J. M., and Lemmon, M. J. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys., 20: 457-461, 1991.
9. Koch, C. J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res., 53: 3992-3997, 1993.
10. Lartigau, E., and Guichard, M. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumor cell lines at clinically relevant partial oxygen pressure? Int. J. Radiat. Biol., 67: 211-216, 1995.
11. Yang, B., Keshelava, N., Anderson, C. P., and Reynolds, C. P. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Cancer Res., 63: 1520-1526, 2003.
12. Brown, J. M., and Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumor. Cancer Res., 50: 7745-7749, 1990.
13. Siim, B. G., Menke, D. R., Dorie, M. J., and Brown, J. M. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res., 57: 2922-2928, 1997.
14. Dorie, M. J., and Brown, J. M. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res., 53: 4633-4636, 1993.
15. Dorie, M. J., and Brown, J. M. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother. Pharmacol., 39: 361-366, 1997.
16. Kovacs, M. S., Hocking, D. J., Evans, J. W., Siim, B. G., Wouters, B. G., and Brown, J. M. Cisplatin anti-tumor potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br. J. Cancer, 80: 1245-1251, 1999.
17. Papadopoulou, M. V., Ji, M., and Bloomer, W. D. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chemother. Pharmacol., 48: 160-168, 2001.
18. Johnson, C. A., Kilpatrick, D., von Roemeling, R., Langer, C., Graham, M. A., Greenslade, D., Kennedy, G., Keenan, E., and O'Dwyer, P. J. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J. Clin. Oncol., 15: 773-780, 1997.
19. Miller, V. A., Ng, K. K., Grant, S. C., Kindler, H., Pizzo, B., Heelan, R. T., von Roemeling, R., and Kris, M. G. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol., 8: 1269-1271, 1997.
20. Bedikian, A. Y., Legha, S. S., Eton, O., Buzaid, A. C., Papadopoulos, N., Coates, S., Simmons, T., Neefe, J., and von Roemeling, R. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann. Oncol., 8: 363-367, 1997.
21. Lee, D. J., Trotti, A., Spencer, S., Rostock, R., Fisher, C., von Roemeling, R., Harvey, E., and Groves, E. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. Int. J. Radiat. Oncol. Biol. Phys., 42: 811-815, 1998.
22. Craighead, P. S., Pearcey, R., and Stuart, G. A Phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys., 48: 791-795, 2000.
23. Del Rowe, J., Scott, C., Werner-Wasik, M., Bahary, J. P., Curran, W. J., Urtasun, R. C., and Fisher, B. J. Single-arm, open-label Phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. Clin. Oncol., 18: 1254-1259, 2000.
24. von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., Talbot, D., Rey, A., Butler, T. W., Hirsh, V., Olver, I., Bergman, B., Ayoub, J., Richardson, G., Dunlop, D., Arcenas, A., Vescio, R., Viallet, J., and Treat, J. J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J. Clin. Oncol., 18: 1351-1359, 2000.
25. Wang, J., Biedermann, K. A., Wolf, C. R., and Brown, J. M. Metabolism of the bioreductive cytotoxin SR 4233 by tumor cells: enzymatic studies. Br. J. Cancer, 67: 321-325, 1993.
26. Patterson, A. V., Saunders, M. P., Chinje, E. C., Patterson, L. H., and Stratford, I. J. Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des., 13: 541-573, 1998.
27. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys., 29: 427-431, 1994.
28. Patterson, A. V., Barham, H. M., Chinje, E. C., Adams, G. E., Harris, A. L., and Stratford, I. J. Importance of P450 reductase activity in determining sensitivity of breast tumor cells to the bioreductive drug, tirapazamine (SR 4233). Br. J. Cancer, 72: 1144-1150, 1995.
29. Patterson, A. V., Saunders, M. P., Chinje, E. C., Talbot, D. C., Harris, A. L., and Strafford, I. J. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br. J. Cancer, 76: 1338-1347, 1997.
30. Jounaidi, Y., and Waxman, D. J. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res., 60: 3761-3769, 2000.
31. Dachs, G. U., and Stratford, I. J. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. Br. J. Cancer, 27 (Suppl.): S126-S132, 1996.
32. Dachs, G. U., Patterson, A. V., Firth, J. D., Ratcliffe, P. J., Townsend, K. M., Stratford, I. J., and Harris, A. L. Targeting gene expression to hypoxic tumor cells. Nat. Med., 3: 515-520, 1997.
33. Semenza, G. L., and Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol., 12: 5447-5454, 1992.
34. Binley, K., Askham, Z., Martin, L., Spearman, H., Day, D., Kingsman, S., and Naylor, S. Hypoxia-mediated tumor targeting. Gene Ther., 10: 540-549, 2003.
35. Bilbao, R., Gerolami, R., Bralet, M. P., Qian, C., Tran, P. L., Tennant, B., Prieto, J., and Brechot, C. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther., 7: 657-662, 2000.
36. Koshikawa, N., Takenaga, K., Tagawa, M., and Sakiyama, S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res., 60: 2936-2941, 2000.
37. Shibata, T., Giaccia, A. J., and Brown, J. M. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia, 4: 40-48, 2002.
38. Amellem, O., and Pettersen, E. O. Cell cycle progression in human cells following re-oxygenation after extreme hypoxia: consequences concerning initiation of DNA synthesis. Cell Prolif., 24: 127-141, 1991.
39. Patterson, A. V., Williams, K. J., Cowen, R. L., Jaffar, M., Telfer, B. A., Saunders, M., Airley, R., Honess, D., van der Kogel, A. J., Wolf, C. R., and Stratford, I. J. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumors. Gene Ther., 9: 946-954, 2002.
40. Fuchs, T., Chowdhury, G., Barnes, C. L., and Gates, K. S. 3-Amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). J. Org. Chem., 66: 107-114, 2001.
41. Chinje, E. C., Patterson, A. V., Saunders, M. P., Lockyer, S. D., Harris, A. L., and Stratford, I. J. Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines? Br. J. Cancer, 81: 1127-1133, 1999.
42. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 15: 936-942, 1987.
43. Workman, P., Balmain, A., Hickman, J. A., McNally, N. J., Rohas, A. M., Mitchison, N. A., Pierrepoint, C. G., Raymond, R., Rowlatt, C., and Stephens, T. C. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab. Anim., 22: 195-201, 1988.
44. Evans, J. W., Yudoh, K., Delahoussaye, Y. M., and Brown, J. M. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res., 58: 2098-2101, 1998.
45. Delahoussaye, Y. M., Evans, J. W., and Brown, J. M. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem. Pharmacol., 62: 1201-1209, 2001.
46. Binley, K., Iqball, S., Kingsman, A., Kingsman, S., and Naylor, S. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther., 6: 1721-1727, 1999.